
Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032
Description
Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032
Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032
Latin America Anti-Obesity Drugs Market Outlook
The global anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032. The market is poised to secure a value of USD 6.3 billion by 2032, driven by the rising prevalence of obesity among children and teenagers across the region.
Key Takeaways
- According to the report released by the United Nations, Overview of Food Security and Nutrition 2022, almost one-fourth (22.5%) of the Latin American population is unable to afford a healthy meal in comparison to the world approximately priced at USD 3.89 per person per day.
- The increasing prevalence of obesity due to the adaption of a sedentary lifestyle along with unhealthy dietary habits are significant factors driving the Latin America anti-obesity drugs market growth in the forecast period.
- The regional market is witnessing high incidence of anti-obesity drugs, which is likely to boost the market share in the forecast period. In February 2023, Tesofensine received positive opinions from Mexican Food and Drug Administration.
Obesity is a growing problem globally and is significantly contributing to high rates of health issues. Therefore, battling this condition is a major necessity of the hour. The Latin American region is facing major health issues related to obesity among children, teenagers, and adults. In August 2023, UNICEF released a report which highlighted that more than 4 million children aged 5 years or less were overweight in Latin American and Caribbean region.
Latin America anti-obesity drugs market share is estimated to be influenced by the approval of drugs by regional regulatory authorities. For instance, in December 2019, Medix, a Mexican pharmaceutical company submitted a New Drug Application (NDA) to the Mexican Food and Drug Administration COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for the approval of tesofensine (a monoamine uptake inhibitor), which can be used for treating obesity in patients. Tesofensine has demonstrated effective loss results in phase II studies in obese patients. After a long wait, on February 26, 2023, the tesofensine was provided a favourable opinion by the Mexican regulatory authority for the treatment of obese patients. Considering the efficacy provided by tesofensine in the clinical trial, a potential interest from both healthcare providers and patients is anticipated, propelling the market growth. The competitive landscape is also expected to be driven by the approval of tesofensine.
Latin America anti-obesity drugs market demand is likely to be propelled by the alarmingly increasing obesity rates. It has been highlighted that the current prevalence rate in Latin America is above the global average, and it has been rising over the last two decades at a sustained rate. Additionally, it contributes to various other health concerns such as hypertension, high cholesterol, diabetes, cardiovascular disease, and even cancer. Addressing obesity among people at early stages is a major precaution that can play a crucial role in timely treatments and overall increased the life expectancy of obese population in the region.
Latin America Anti-Obesity Drugs Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
- Semaglutide
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Liraglutide
- Gelesis 100
- Orlistat
- Phentermine
- Methamphetamine
- Tirzepatide
- Amphetamine
- GLP-1 Receptor Agonist
- Lipase Inhibitor
- Centrally Acting Drugs
- Peripherally Acting Drugs
- Oral
- Subcutaneous
- Prescription Drugs
- Over The Counter Drugs
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Pharmacies
- Brazil
- Argentina
- Mexico
- Others
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- VIVUS Inc.
- Pfizer, Inc.
- Novo Nordisk
- Bayer AG
- F Hoffmann-La-Roche
- Glaxosmithkline
- Arena Pharmaceuticals
- Eisai Co. Ltd
- Takeda Pharmaceutical Company
- Nalpropion Pharmaceuticals Inc
FAQs
- What was the Latin America anti-obesity drugs market forecast outlook for 2024-2032?
- What are the major factors aiding the Latin America anti-obesity drugs market demand?
- What are the major Latin America anti-obesity drugs market trends?
- What is the market segmentation by drugs?
and Tirzepatide.
- What drug classes are available in the market?
- How many categories are based on the mechanism of action?
- What are the various routes of administration for anti-obesity drugs?
- What is the segmentation based on prescription types?
- What is the market segmentation based on distribution channels?
- What is the market segmentation by country?
Who are the key players involved in the Latin America anti-obesity drugs market?
The key players in the market are and VIVUS Inc., Nalpropion Pharmaceuticals Inc., Pfizer, Inc., Novo Nordisk, Bayer AG, F Hoffmann-La-Roche, GlaxoSmithKline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company.
Meta description
The Latin America anti-obesity drugs market size is poised for growth, driven by the expansion of the global market, which was valued at USD 2.5 billion in 2023 and is projected to grow at a CAGR of 10.70% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Anti-Obesity Drugs Market Overview
- 3.1 Latin America Anti-Obesity Drugs Market Historical Value (2017-2023)
- 3.2 Latin America Anti-Obesity Drugs Market Forecast Value (2024-2032)
- 4 Latin America Anti-Obesity Drugs Market Landscape*
- 4.1 Latin America Anti-Obesity Drugs Market: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Latin America Anti-Obesity Drugs Market: Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Material
- 4.2.3 Analysis by Type
- 5 Latin America Anti-Obesity Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Latin America Anti-Obesity Drugs Market Segmentation (2017-2032)
- 6.1 Latin America Anti-Obesity Drugs Market (2017-2032) by Drugs
- 6.1.1 Market Overview
- 6.1.2 Semaglutide
- 6.1.3 Phentermine/Topiramate
- 6.1.4 Naltrexone/Bupropion
- 6.1.5 Liraglutide
- 6.1.6 Gelesis 100
- 6.1.7 Orlistat
- 6.1.8 Phentermine
- 6.1.9 Methamphetamine
- 6.1.10 Tirzepatide
- 6.2 Latin America Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 6.2.1 Market Overview
- 6.2.2 Amphetamine
- 6.2.3 GLP-1 receptor agonist
- 6.2.4 Lipase Inhibitor
- 6.3 Latin America Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 6.3.1 Market Overview
- 6.3.2 Centrally Acting Drugs
- 6.3.3 Peripherally Acting Drugs
- 6.4 Latin America Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 6.4.1 Market Overview
- 6.4.2 Oral
- 6.4.3 Subcutaneous
- 6.5 Latin America Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 6.5.1 Market Overview
- 6.5.2 Prescription Drugs
- 6.5.3 Over The Counter Drugs
- 6.6 Latin America Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 6.6.1 Market Overview
- 6.6.2 Hospital Pharmacies
- 6.6.3 Drug Store & Retail Pharmacies
- 6.6.4 Online Pharmacies
- 6.7 Latin America Anti-Obesity Drugs Market (2017-2032) by Countries
- 6.7.1 Market Overview
- 6.7.2 Brazil
- 6.7.3 Argentina
- 6.7.4 Mexico
- 6.7.5 Others
- 7 Brazil Anti-Obesity Drugs Market (2017-2032)
- 7.1 Brazil Anti-Obesity Drugs Market (2017-2032) by Drugs
- 7.1.1 Market Overview
- 7.1.2 Semaglutide
- 7.1.3 Phentermine/Topiramate
- 7.1.4 Naltrexone/Bupropion
- 7.1.5 Liraglutide
- 7.1.6 Gelesis 100
- 7.1.7 Orlistat
- 7.1.8 Phentermine
- 7.1.9 Methamphetamine
- 7.1.10 Tirzepatide
- 7.2 Brazil Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 7.2.1 Market Overview
- 7.2.2 Amphetamine
- 7.2.3 GLP-1 receptor agonist
- 7.2.4 Lipase Inhibitor
- 7.3 Brazil Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 7.3.1 Market Overview
- 7.3.2 Centrally Acting Drugs
- 7.3.3 Peripherally Acting Drugs
- 7.4 Brazil Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 7.4.1 Market Overview
- 7.4.2 Oral
- 7.4.3 Subcutaneous
- 7.5 Brazil Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 7.5.1 Market Overview
- 7.5.2 Prescription Drugs
- 7.5.3 Over The Counter Drugs
- 7.6 Brazil Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 7.6.1 Market Overview
- 7.6.2 Hospital Pharmacies
- 7.6.3 Drug Store & Retail Pharmacies
- 7.6.4 Online Pharmacies
- 8 Argentina Anti-Obesity Drugs Market (2017-2032)
- 8.1 Argentina Anti-Obesity Drugs Market (2017-2032) by Drugs
- 8.1.1 Market Overview
- 8.1.2 Semaglutide
- 8.1.3 Phentermine/Topiramate
- 8.1.4 Naltrexone/Bupropion
- 8.1.5 Liraglutide
- 8.1.6 Gelesis 100
- 8.1.7 Orlistat
- 8.1.8 Phentermine
- 8.1.9 Methamphetamine
- 8.1.10 Tirzepatide
- 8.2 Argentina Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 8.2.1 Market Overview
- 8.2.2 Amphetamine
- 8.2.3 GLP-1 receptor agonist
- 8.2.4 Lipase Inhibitor
- 8.3 Argentina Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 8.3.1 Market Overview
- 8.3.2 Centrally Acting Drugs
- 8.3.3 Peripherally Acting Drugs
- 8.4 Argentina Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 8.4.1 Market Overview
- 8.4.2 Oral
- 8.4.3 Subcutaneous
- 8.5 Argentina Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 8.5.1 Market Overview
- 8.5.2 Prescription Drugs
- 8.5.3 Over The Counter Drugs
- 8.6 Argentina Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 8.6.1 Market Overview
- 8.6.2 Hospital Pharmacies
- 8.6.3 Drug Store & Retail Pharmacies
- 8.6.4 Online Pharmacies
- 9 Mexico Anti-Obesity Drugs Market (2017-2032)
- 9.1 Mexico Anti-Obesity Drugs Market (2017-2032) by Drugs
- 9.1.1 Market Overview
- 9.1.2 Semaglutide
- 9.1.3 Phentermine/Topiramate
- 9.1.4 Naltrexone/Bupropion
- 9.1.5 Liraglutide
- 9.1.6 Gelesis 100
- 9.1.7 Orlistat
- 9.1.8 Phentermine
- 9.1.9 Methamphetamine
- 9.1.10 Tirzepatide
- 9.2 Mexico Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 9.2.1 Market Overview
- 9.2.2 Amphetamine
- 9.2.3 GLP-1 receptor agonist
- 9.2.4 Lipase Inhibitor
- 9.3 Mexico Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 9.3.1 Market Overview
- 9.3.2 Centrally Acting Drugs
- 9.3.3 Peripherally Acting Drugs
- 9.4 Mexico Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 9.4.1 Market Overview
- 9.4.2 Oral
- 9.4.3 Subcutaneous
- 9.5 Mexico Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 9.5.1 Market Overview
- 9.5.2 Prescription Drugs
- 9.5.3 Over The Counter Drugs
- 9.6 Mexico Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
- 9.6.1 Market Overview
- 9.6.2 Hospital Pharmacies
- 9.6.3 Drug Store & Retail Pharmacies
- 9.6.4 Online Pharmacies
- 10 Regulatory Framework
- 11 Patent Analysis
- 11.1 Analysis by Type of Patent
- 11.2 Analysis by Publication year
- 11.3 Analysis by Issuing Authority
- 11.4 Analysis by Patent Age
- 11.5 Analysis by CPC Analysis
- 11.6 Analysis by Patent Valuation
- 11.7 Analysis by Key Players
- 12 Funding and Investment Analysis
- 12.1 Analysis by Funding Instances
- 12.2 Analysis by Type of Funding
- 12.3 Analysis by Funding Amount
- 12.4 Analysis by Leading Players
- 12.5 Analysis by Leading Investors
- 12.6 Analysis by Geography
- 13 Partnership and Collaborations Analysis
- 13.1 Analysis by Partnership Instances
- 13.2 Analysis by Type of Partnership
- 13.3 Analysis by Leading Players
- 13.4 Analysis by Geography
- 14 Supplier Landscape
- 14.1 Market Share by Top 5 Companies
- 14.2 VIVUS Inc
- 14.2.1 Financial Analysis
- 14.2.2 Product Portfolio
- 14.2.3 Demographic Reach and Achievements
- 14.2.4 Mergers and Acquisitions
- 14.2.5 Certifications
- 14.3 Pfizer, Inc.
- 14.3.1 Financial Analysis
- 14.3.2 Product Portfolio
- 14.3.3 Demographic Reach and Achievements
- 14.3.4 Mergers and Acquisitions
- 14.3.5 Certifications
- 14.4 Novo Nordisk
- 14.4.1 Financial Analysis
- 14.4.2 Product Portfolio
- 14.4.3 Demographic Reach and Achievements
- 14.4.4 Mergers and Acquisitions
- 14.4.5 Certifications
- 14.5 Bayer AG
- 14.5.1 Financial Analysis
- 14.5.2 Product Portfolio
- 14.5.3 Demographic Reach and Achievements
- 14.5.4 Mergers and Acquisitions
- 14.5.5 Certifications
- 14.6 F Hoffmann-La Roche
- 14.6.1 Financial Analysis
- 14.6.2 Product Portfolio
- 14.6.3 Demographic Reach and Achievements
- 14.6.4 Mergers and Acquisitions
- 14.6.5 Certifications
- 14.7 Glaxosmithkline
- 14.7.1 Financial Analysis
- 14.7.2 Product Portfolio
- 14.7.3 Demographic Reach and Achievements
- 14.7.4 Mergers and Acquisitions
- 14.7.5 Certifications
- 14.8 Arena Pharmaceuticals
- 14.8.1 Financial Analysis
- 14.8.2 Product Portfolio
- 14.8.3 Demographic Reach and Achievements
- 14.8.4 Mergers and Acquisitions
- 14.8.5 Certifications
- 14.9 Eisai Co. Ltd
- 14.9.1 Financial Analysis
- 14.9.2 Product Portfolio
- 14.9.3 Demographic Reach and Achievements
- 14.9.4 Mergers and Acquisitions
- 14.9.5 Certifications
- 14.10 Takeda Pharmaceutical Company
- 14.10.1 Financial Analysis
- 14.10.2 Product Portfolio
- 14.10.3 Demographic Reach and Achievements
- 14.10.4 Mergers and Acquisitions
- 14.10.5 Certifications
- 14.11 Nalpropion Pharmaceuticals Inc
- 14.11.1 Financial Analysis
- 14.11.2 Product Portfolio
- 14.11.3 Demographic Reach and Achievements
- 14.11.4 Mergers and Acquisitions
- 14.11.5 Certifications
- 15 Latin America Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
- 15.1 Overview
- 15.2 Potential Distributors
- 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 17 Company Competitiveness Analysis (Additional Insight)
- 17.1 Very Small Companies
- 17.2 Small Companies
- 17.3 Mid-Sized Companies
- 17.4 Large Companies
- 17.5 Very Large Companies
- 18 Payment Methods (Additional Insight)
- 18.1 Government Funded
- 18.2 Private Insurance
- 18.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.